Retina

OPGx-LCA5 is designed to address a form of Leber congenital amaurosis that results from biallelic mutations in the LCA5 gene, which encodes the lebercilin protein, the investigators explained.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform treatment and improve children's vision.

Tsu Shan Chambers shares how the film "My Eyes" uses authentic storytelling to raise awareness of inherited eye disease and the importance of preventive vision care.

The EXTEND trial provided 5-year follow-up for 10 patients with advanced retinitis pigmentosa, who had previously received MCO-010 during a phase 1/2a trial

The addition comes as the company accelerates development of its long-acting anti-VEGF program and advances its HA-binding platform.

The EXTEND study is a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial.

The funding will support the completion of the clinical PoC of its AAVB-039 CELESTE study and the completion of the STELLA natural history study

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists considering this approach.

Tsu Shan Chambers, optometrist and filmmaker, blends clinical insight and storytelling to highlight preventable vision loss, retinitis pigmentosa, and the power of ability over disability in her socially conscious film.

Deborah A. Ferrington, PhD, highlights how breakthroughs in imaging, AI, and stem cell research are reshaping ophthalmology.

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient awareness and surgical presence.

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

SPVN20 is a gene-agnostic, intravitreal AAV-based gene therapy that targets dormant cones to restore vision, according to SparingVision

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

The satellite of the US-based University of Miami Health System will offer a “full spectrum of ophthalmic services” in the United Arab Emirates

Reporting from the European Society of Retina Specialists annual congress

Catch up on news you may have missed at the meeting in Orlando, like the effects of GLP-1 drugs on eye health and a potential sign of cardiovascular disease.

David Eichenbaum, MD, FASRS, recalls an early-career case managing bilateral diabetic macular edema with frequent intravitreal triamcinolone injections—leading to severe steroid-induced glaucoma and valve implants.

Anat Loewenstein, MD, shared recent research findings which indicate home monitoring is appropriate for atypical and complex pathologies

REMAIN is the long-term extension of the phase 2b/3 RESTORE trial evaluating MCO-010 in retinitis pigmentosa (RP).

HELIOS Phase 1 showed consistent reductions in retinal fluid with OTX-TKI, paving the way for pivotal HELIOS-2 and HELIOS-3 trials.